Day: January 20, 2026

RYE, N.Y., Jan. 20, 2026 (GLOBE NEWSWIRE) — Investors looking to learn about the often-overlooked asset class of closed-end funds are invited to visit The Closed-End Corner on Gabelli TV and YouTube. The Closed-End Fund Corner has produced a series of educational videos on topics currently threatening Closed-End Funds. To view the videos, please click on the link below: https://gabelli.com/insights/gabelli-media/gabelli-closed-end-corner/ Videos include: Back To The Future With Closed-End Funds Looks at the history of Closed-End Funds and traces their remarkable growth since 1985, the year Back To The Future premiered. At that time, closed-end funds Net Asset Values were only published weekly in newspapers and numbered about 25 with some dating back to before the depression. Short-Term Value Extraction vs. Long-Term Value Creation...

Vancouver, B.C. , Jan. 20, 2026 (GLOBE NEWSWIRE) — WestKam Gold Corp. (the “Company” or “WestKam”) is pleased to announce the results of a helicopter-assisted, soil sampling survey completed on the Will Claim.  The sampling program was conducted in late September 2025 to test gossanous areas interred to contain altered ultramafics on the Company’s 100%-owned Will Project, located on Mt. Williams near Goldbridge, British Columbia. The Will Project encompasses 1,142.47 hectares of highly prospective terrain and is in good standing through January 30, 2027. The 2025 exploration program focused on a zone of listwanite alteration in the upper reaches of Mt. Williams, an area with geological characteristics conducive to gold and antimony mineralization. The targeted alteration zone is situated on trend with the Minto-Olympic shear zone,...

MCLEAN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Mission Technologies division is among 12 companies included on a 10-year, $25.4 billion Advanced Technology Support Program V (ATSP5) multiple award indefinite delivery/indefinite quantity contract to provide engineering solutions for electronics and software problems. Awarded by the Defense Microelectronics Activity, ATSP5 is used across the U.S. Department of Defense and other civilian federal agencies to rapidly obtain advanced microelectronics, engineering, prototyping and technology modernization support. The contract provides rapid, flexible access to advanced microelectronics technologies, solves operational problems caused by obsolescence and accelerates deployment. “Delivering a trusted, assured supply of microelectronics directly impacts...

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology. The publication, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” details the comprehensive positive results previously announced by the Company on May 6, 2025. This marks the first study to integrate TSPO-PET imaging, proteomics, and clinical assessments in...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a leader in Agentic Commerce and AI-powered customer engagement, today announced that it has entered into securities purchase agreements led by existing and new fundamental institutional investors for the purchase and sale of 62,500,000 ordinary shares at a purchase price of $4.00 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $250 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 21, 2026, subject to the satisfaction of customary closing conditions.  The Company intends to use the net proceeds from the offering for accelerated investment into its sales organization, potential accretive M&A opportunities...

CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued operational growth and infrastructure expansion at Cosmofarm, its pharmaceutical distribution subsidiary in Greece. During 2025, Cosmofarm added nearly 100 new pharmacy customers, representing a weighted average increase of approximately 20% in its active customer base. This growth was accompanied by improved unit economics, with annual revenue per customer increasing by approximately 12% and profitability per customer improving by approximately 14%, driven by enhanced route density, optimized order execution, and increasing operational leverage. Based on current onboarding activity and demand trends, management expects...

Baltic Horizon Capital AS, the management company of Baltic Horizon Fund, hereby informs of changes in the management board. Edvinas Karbauskas has been proposed for appointment as a member of the management board of Baltic Horizon Capital AS. Edvinas will commence his employment with Baltic Horizon Capital AS starting from 2 February 2026 and, after approval of the Estonian Financial Supervision and Resolution Authority, will become member of the management board and Co-fund Manager of Baltic Horizon Fund together with Tarmo Karotam, the current Fund Manager. Edvinas is expected to rejoin the management board, bringing with him valuable continuity and experience as he previously served as a board member of Baltic Horizon Capital AS from January 2023 to June 2024, during which time he held the position of co-fund manager. Since stepping...

SEOUL and SHENZHEN, China and WILMINGTON, N.C., Jan. 20, 2026 (GLOBE NEWSWIRE) — MBAK Energy Solutions, Inc. (OTC:MBAK) is pleased to welcome Tony W. Tsai as Chief Strategist and Business Development Officer and Al Vaks as Business Development Manager for the Middle East and North Africa (MENA). Tony and Al bring a wealth of talent and experience in market development, compliance, and sector expertise that will further position the company to capitalize on its 2025 successes and continue to grow into the sustainable energy management and electric mobility sectors. Tony Tsai is a seasoned leader and organizational builder across a range of enterprises. While serving as the Vice President of Corporate Affairs for a pioneering commercial EV truck manufacturer, he built the company’s core functions, including Operations, Human Resources,...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine in NSCLC advances concurrent Phase 2 expansion and Phase 3 trials along strategic regulatory pathways Strong momentum toward goal of early commercial approval Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements and highlighted key targeted milestones...